Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial.
AF, atrial fibrillation
CV, cardiovascular
GDMT, guideline-directed medical therapy
GUIDE-IT, Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment in Heart Failure trial
HF, heart failure
HFrEF, heart failure with reduced ejection fraction
KCCQ, Kansas City Cardiomyopathy Questionnaire
NT-proBNP, N-terminal pro–B type natriuretic peptide
RCT, randomized controlled trial
Journal
Mayo Clinic proceedings. Innovations, quality & outcomes
ISSN: 2542-4548
Titre abrégé: Mayo Clin Proc Innov Qual Outcomes
Pays: Netherlands
ID NLM: 101728275
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
To evaluate effects of atrial fibrillation (AF) on cardiac biomarkers and outcomes in a trial population of patients with heart failure (HF) with reduced ejection fraction treated with optimal guideline-directed medical therapy. We performed a secondary analysis of 894 patients in the Guiding Evidence-Based Therapy Using Biomarker-Intensified Treatment in Heart Failure (GUIDE-IT) trial (January 2013-July 2016). Patients were stratified by AF status and compared with regard to guideline-directed medical therapy use, longitudinal levels of N-terminal pro-B type natriuretic peptide (NT-proBNP), and outcomes including HF hospitalization and mortality. After adjustment, AF was associated with a significant increase in the risk of HF hospitalization or cardiovascular death (hazard ratio, 1.28; 95% CI, 1.02 to 1.61; Among patients with HF with reduced ejection fraction, prevalent AF was associated with higher NT-proBNP concentrations through 2 years of follow-up and higher risk for HF hospitalization despite no substantial differences in medical therapy.
Identifiants
pubmed: 33997640
doi: 10.1016/j.mayocpiqo.2021.02.005
pii: S2542-4548(21)00038-2
pmc: PMC8105522
doi:
Types de publication
Journal Article
Langues
eng
Pagination
447-455Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001864
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.
Références
Circulation. 2003 Mar 11;107(9):1278-83
pubmed: 12628948
Circulation. 1991 Jul;84(1):40-8
pubmed: 2060110
Eur Heart J. 2015 Dec 7;36(46):3250-7
pubmed: 26419625
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Am Coll Cardiol. 2017 Nov 14;70(20):2490-2500
pubmed: 29145948
Circulation. 1998 Sep 8;98(10):946-52
pubmed: 9737513
Circulation. 2009 May 12;119(18):2516-25
pubmed: 19433768
Circ Heart Fail. 2017 Oct;10(10):
pubmed: 29018174
N Engl J Med. 2016 Apr 21;374(16):1521-32
pubmed: 27043774
Lancet. 2014 Dec 20;384(9961):2235-43
pubmed: 25193873
Am J Med. 2014 Oct;127(10):963-71
pubmed: 24931393
Circulation. 2003 Jun 17;107(23):2920-5
pubmed: 12771006
J Am Coll Cardiol. 2018 Nov 27;72(21):2551-2562
pubmed: 30466512
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
N Engl J Med. 2018 Feb 01;378(5):417-427
pubmed: 29385358
JACC Heart Fail. 2014 Oct;2(5):457-65
pubmed: 25194287
J Am Coll Cardiol. 2006 May 16;47(10):1997-2004
pubmed: 16697316
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
Eur J Heart Fail. 2006 Aug;8(5):539-46
pubmed: 16567126
Eur Heart J. 2005 Jul;26(13):1303-8
pubmed: 15767288
Circulation. 2006 Jun 13;113(23):2713-23
pubmed: 16754803
Eur J Heart Fail. 2007 May;9(5):502-9
pubmed: 17174599
JAMA. 2017 Aug 22;318(8):713-720
pubmed: 28829876
Eur J Heart Fail. 2009 Jul;11(7):676-83
pubmed: 19553398
J Am Coll Cardiol. 2014 Aug 19;64(7):710-21
pubmed: 25125304